Funding for Faculty

Siteman Funding Opportunities Newsletter

Download the latest Siteman Funding Opportunities Newsletter (PDF)

The newsletter and the list of open opportunities on this page are not fully inclusive of all available cancer-related funding. Please be sure to consult other sources to learn of other opportunities not listed here.

September Deadlines

September 30: Alternative and Integrative Pancreatic Research Grant – National Pancreatic Cancer Foundation

Additional Details

RFP Snapshot: In an effort to improve the survival rate for pancreatic cancer, support compassionate quality of life care and to spread hope, NPCF is proud to fund Alternative and Integrative Research for the treatment of pancreatic cancer. Applications for research project proposals must clearly show that the scope of the research project priorities are in order and compliance with alternative and integrative research for pancreatic cancer treatment and therapies.

Max Amount and Period: $30,000 for 1 year

Eligibility: No specific limitations or requirements are set regarding the level of education, credentialing or level of effort required by the Principal Investigator or other key personnel for grant eligibility.

Due Date: Letter of Intent Due: September 30, 2022 at 4PM CST

September 30 LOI: Myeloma Accelerator Challenge Program Grants – Multiple Myeloma Research Foundation

Additional Details

RFP Snapshot: This RFA seeks applications in two areas of high unmet need: 1) optimizing first-line therapy for high-risk, newly-diagnosed Multiple Myeloma and 2) high-risk smoldering multiple myeloma. Applicants will form multi-institutional, collaborative research networks for preclinical and translational projects, with a primary goal of developing novel, hypothesis driven clinical trial concept(s) in each of these two areas of unmet need.

Max Amount and Period: $10M over 3 years

Eligibility: The Program Study Director and co-Principal Investigators must hold an M.D., Ph.D., or equivalent degree, and be from not-for-profit 501(c) 3 organizations, or their international counterparts/equivalents, including universities, colleges, hospitals, research organizations and/or clinical laboratories. Collaborative research networks must contain at least 3 separate research institutions who will collectively assemble the appropriate assays, tools and models to study critical research questions that can be rapidly translated into novel treatment approaches for HR-NDMM and HR-SMM patients. The network should include investigators with expertise in basic, translational, computational/bioinformatics and clinical research focused on different types of immune and/or targeted therapeutic approaches.

Due Date: Letter of Intent Due: September 30, 2022 at 10:59PM CST

September 30: Alternative and Integrative Research Grant – National Pancreatic Cancer Foundation

Additional Details

RFP Snapshot: Research funding is restricted to alternative and integrative treatments and therapies for the benefit of pancreatic cancer patients. Applications for research project proposals must clearly show that the scope of the research project priorities are in order and compliance with alternative and integrative research for pancreatic cancer treatment and therapies.

Max Amount and Period: $10,000 to $30,000 for 1 year

Eligibility: No specific eligibility requirements are set regarding the level of education, credentialing or level of effort required by the PI or other key personnel.

Due Date: September 30, 2022 at 4PM CST

October Deadlines

October 3: The Last Mile Sarcoma Research Award – Sarcoma Foundation of America

Additional Details

RFP Snapshot: This opportunity is to support translational science research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human sarcomas and is specifically meant to provide funding to strengthen the first resubmission of a NCI R01 proposal that scored in the 30th percentile or better (but outside the current NCI pay line).

Max Amount and Period: $150,000 for 1 year

Eligibility: Applicants must be a MD, DO, PhD, or equivalent and within the first seven years of faculty appointment.

Due Date: October 3, 2022 at 4PM CST

October 5: Melanoma Patient-Centric Clinical Trial Team Science Awards – Melanoma Research Alliance and the Rising Tide Foundation for Clinical Cancer Research

Additional Details

RFP Snapshot: The MRA and RTFCCR will jointly support two team awards for clinical trials with the potential to provide substantial impact to melanoma patients. These awards seek to support novel, interventional clinical trials with the goal of making a significant difference to melanoma patients in the short term. Patient engagement must be actively demonstrated throughout the full life cycle of the clinical trial, including planning and dissemination. We welcome applications from all research groups with a track record in melanoma. Grant applicants should actively involve patients in the protocol design.

Max Amount and Period: $1.5M over 5 years

Eligibility: PIs must hold a full-time faculty appointment at the level of Assistant Professor (or equivalent) or above and be able to show clear evidence of an independent research program. The team must be multidisciplinary, and consist of two or more established Principal Investigators, one of whom is designated the Administrative PI, a Young Investigator with complementary expertise, and a Mentor for the Young Investigator.

Due Date: October 5, 2022 at 10:59PM CST

October 11 LOI: 2023 ALSF Innovation Grant – Alex’s Lemonade Stand Foundation

Additional Details

RFP Snapshot: The Innovation Grant is designed to provide critical and significant seed funding for researchers with a novel approach to pediatric oncology scientific investigation. Proposals should have clinical translation in view. This may represent a change in research direction and/or an innovative new idea that moves away from an investigator’s prior research but for which a strong case is made for the potential impact on childhood cancers.

Max Amount and Period: $250,000 over 2 years

Eligibility: Applicants must have a MD, PhD, or MD/PhD or equivalent and have a track record of publication and funding productivity that demonstrates the project can be accomplished. Applicant must propose a new research direction, not a continuation of ongoing funded research. Applicants need not be U.S. citizens.

Due Date: Letter of Intent Due: October 11, 2022 at 7PM CST

October 15: Paul Calabresi K12 Development Award Program in Clinical Oncology – NIH/NCI

Additional Details

RFP Snapshot: The Paul Calabresi K12 Career Development Award Program in Clinical Oncology is designed to train a new generation of highly skilled investigators with specialized expertise who will be well prepared to lead cancer research. It supports the development of postdoctoral scholars and junior faculty through patient oriented cancer research training, curricula, and mentored projects.

Max Amount and Period: 75% salary (up to $100,000) and $25,000 for research, travel, and tuition per year over 2 years

Eligibility: Eligible applicants are Instructors and Assistant Professors with a clinical doctoral degree and US citizenship or permanent US visa.

Due Date: October 15, 2022 at 5PM CST

October 15: ACS Stage 1 Mission Boost Grants (MBG) – American Cancer Society

Additional Details

RFP Snapshot: Mission Boost Grants (MBG) are designed to support select current and past ACS grantees specifically for the translation of their research to human testing. Mission Boost Grants are opportunities for ACS grantees to seek additional, or “boost,” resources for innovative, high-risk/high-reward projects. Stage 1 Mission Boost requires the investigator to develop outcome-specific, unequivocal milestones that reduce the risks of studying a new drug, device, or procedure in patients. The topic of study may be the same that was previously funded by the ACS grant, but it is not required to be. Stage I MBG studies can be preclinical or clinical in nature.

Max Amount and Period: $200,000 over 2 years

Eligibility: Applicants must be either current or past ACS grantees who hold or have held one of the follow grants:

  • Research Scholar Grant (RSG)
  • Clinician Scientist Development Grant (CSDG)
  • Mentored Research Scholar Grant (MRSG)
  • Cancer Control Career Development Awards (CCCDA)
  • Pilot and Exploratory Projects in Palliative Care (PEP) Award
  • ACS Postdoctoral Fellowship (previous fellows only)

The applicant must have held one of the above grants for a minimum of one year.

Due Date: October 15, 2022 at 10:59PM CST  

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing your proposal.

ACS Grants Workshop Webinar: The American Cancer Society is conducting a 90-minute virtual Extramural Discovery Science Grants workshop on Wednesday, Sept. 7 from 1PM to 2:30PM CST. Be sure to register in advance for this meeting!

October 15: ACS Discovery Boost Grants (DBG) – American Cancer Society

Additional Details

RFP Snapshot: Discovery Boost Grants (DBG) support high-risk, high-reward exploratory cancer research across the research continuum. Investigators may focus on developing research methodologies, establishing feasibility, or leading pilot tests.

Max Amount and Period: $200,000 over 2 years

Eligibility: Applicants who have independent faculty appointments at a US academic institution are eligible to apply.

Due Date: October 15, 2022 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing your proposal.

ACS Grants Workshop Webinar: The American Cancer Society is conducting a 90-minute virtual Extramural Discovery Science Grants workshop on Wednesday, Sept. 7 from 1PM to 2:30PM CST. Be sure to register in advance for this meeting!

October 15: ACS Clinician Scientist Development Grant (CSDG) – American Cancer Society

Additional Details

RFP Snapshot: The Clinician Scientist Development Grant (CSDG) supports junior faculty members in becoming independent investigators as clinician scientists. This grant is designed for people trained primarily as clinicians who want to maintain clinical practice and conduct cancer research.

Max Amount and Period: Varies from $405,000 over 3 years to $675,000 over 5 years (dependent on the amount of mentored post-doctoral research training of the applicant)

Eligibility: Eligible applicants play a role in clinical care and are within the first 6 years of starting a full-time faculty appointment. They will have had LESS than 3 years of mentored post-doctoral research experience and have not had an NIH K-type or other mentored award. Applicant must also not have had an R-level or equivalent grant.

Due Date: October 15, 2022 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing your proposal.

ACS Grants Workshop Webinar: The American Cancer Society is conducting a 90-minute virtual Extramural Discovery Science Grants workshop on Wednesday, Sept. 7 from 1PM to 2:30PM CST. Be sure to register in advance for this meeting!

October 15: ASTRO-ACS Clinician Scientist Development Grant (CSDG) – American Cancer Society and ASTRO

Additional Details

RFP Snapshot: The Clinician Scientist Development Grant (CSDG) supports junior faculty members in becoming independent investigators as clinician scientists. This grant is designed for people trained primarily as clinicians who want to maintain clinical practice and conduct cancer research. Specifically for this RFA in partnership with ASTRO, the applicant must be in the radiation oncology field.

Max Amount and Period: Varies from $405,000 over 3 years to $675,000 over 5 years (dependent on the amount of mentored post-doctoral research training of the applicant)

Eligibility: Eligible applicants must be in the radiation oncology field and have a clinical doctoral degree with an active license to provide clinical care. They must be within the first 6 years of starting a full-time faculty appointment. They will have had LESS than 3 years of mentored post-doctoral research experience and have not had a NIH K-type or other mentored award. Applicant must also not have had an R-level or equivalent grant.

Due Date: October 15, 2022 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing your proposal.

October 15: ACS Research Scholar Grants (RSG) – American Cancer Society

Additional Details

RFP Snapshot: Research Scholar Grants (RSG) provide support for independent, self-directed researchers and clinician scientists, who are investigators licensed to provide patient care and trained to conduct research. Grant proposals are investigator-initiated and may pursue questions across the cancer research continuum, as long as they fit within an American Cancer Society (ACS) priority research area.

Max Amount and Period: Varies from $660,000 over 4 years (Focus A) to $1M over 5 years (Focus B)

Eligibility: Focus A: Any ACS Priority Area

Eligible applicants were first appointed as independent, full-time faculty LESS than 10 years ago and are the PI on NO MORE THAN 1  R01 or R01-equivalent grant at the time of submission.

Focus B: Achieving Cancer Health Equity / Health Policy

Eligible applicants can be at any stage of their faculty career and have any amount of funding.

Due Date: October 15, 2022 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing your proposal.

ACS Grants Workshop Webinar: The American Cancer Society is conducting a 90-minute virtual Extramural Discovery Science Grants workshop on Wednesday, Sept. 7 from 1PM to 2:30PM CST. Be sure to register in advance for this meeting!

October 15: ACS Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families – American Cancer Society

Additional Details

RFP Snapshot: The Pilot and Exploratory Project mechanism supports a small pilot or exploratory project to test interventions, develop research methodologies, and explore novel areas in palliative care. A condition of funding is a clearly defined plan as to how the investigator will use the results of the project to develop larger, extramurally funded research projects. Research may focus on one or more of the following: decision-making, treatment, symptom control, team care, or engaging family members and caregivers to address communication barriers and/or optimal symptom management.

Max Amount and Period: $120,000 over 2 years

Eligibility: Only resubmissions of previously reviewed applications are being accepted in the Fall 2022 cycle. Applicants must be at the doctoral level and have full-time faculty appointment. Independent investigators at all stages of their career are eligible to apply. 

Due Date: October 15, 2022 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing your proposal.

ACS Grants Workshop Webinar: The American Cancer Society is conducting a 90-minute virtual Extramural Discovery Science Grants workshop on Wednesday, Sept. 7 from 1PM to 2:30PM CST. Be sure to register in advance for this meeting!

October 15: ACS Role of Health Policy and Health Insurance in Improving Access to and Performance of Cancer Prevention, Early Detection, and Treatment Services – American Cancer Society

Additional Details

RFP Snapshot: ACS is keenly interested in supporting rapid learning research to study the effects of health policy changes on patients, providers, and health systems. This includes but is not limited to: facilitators and barriers to care; unintended consequences; differential experiences and outcomes of patients seeking or receiving care; best practice models for quality care; and economic impact.

Potential research areas include the four As of meaningful healthcare reform: Availability, Affordability, Adequacy, Administrative Simplicity.

Max Amount and Period: Varies from $400,000 over 2 years to $1M over 5 years (health equity projects)

Eligibility: Applicants must be full-time independent investigator at any stage in their career.

Due Date: October 15, 2022 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing your proposal.

ACS Grants Workshop Webinar: The American Cancer Society is conducting a 90-minute virtual Extramural Discovery Science Grants workshop on Wednesday, Sept. 7 from 1PM to 2:30PM CST. Be sure to register in advance for this meeting!

October 18 LOI: Sam Day Foundation Grants

Additional Details

RFP Snapshot: The Sam Day Foundation is interested in innovative research projects with a high likelihood of generating more curative and less toxic therapies to children, adolescents, and young adults with cancer. SDF is focused on the most destructive and challenging cancers in the field of pediatric oncology, and looks to partner with researchers and clinicians who demonstrate a commitment

to creating a better future for young people with cancer.

Max Amount and Period: $50,000 to $250,000 over 1-2 years

Eligibility: No specific investigator eligibility requirements. Projects must focus on the following priorities:

  • Pediatric, adolescent, and young adult sarcoma and brain tumors.
  • Any phase of research from bench to bedside, including correlative studies.
  • SDF is open to research studies focused on nutrition and childhood cancer. Studies that seek to improve long-term health outcomes, treatment tolerance, quality of life, and anti-cancer properties are of interest.
  • Ultra-rare sarcoma and brain tumor research is encouraged and especially favorable in studies that are inclusive of more than one cancer.

Due Date: Letter of Intent Due: October 18, 2022 at Noon CST

October 18 LOI: AACR Pancreatic Early Detection Research Grant – Lustgarten Foundation, Swim Across America, AACR

Additional Details

RFP Snapshot: The Lustgarten Foundation-Swim Across America-AACR Pancreatic Cancer Early Detection Research Grant represents a joint effort to support innovative research to advance efforts towards the early detection and interception of pancreatic cancer. The proposed project may be basic, translational, clinical, or epidemiological in nature, must have direct applicability and relevance to the understanding, detection, diagnosis, or treatment of pancreatic cancer, and be aligned with the goals and priorities of the Lustgarten Foundation.

Max Amount and Period: $300,000 for 3 years

Eligibility: Applicants must have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree. Postdoctoral or clinical research fellows are not eligible to apply. Applications from investigators with experience in other areas of cancer or biomedical research who have promising ideas and approaches that can be applied to pancreatic cancer research are especially encouraged. Applicants must be AACR Active members. Nonmembers can apply for membership here.

Due Date: Letter of Intent Due: October 18, 2022 at Noon CST

October 18 LOI: AACR Career Development Award for Pancreatic Cancer Research in honor of Ruth Bader Ginsburg – Lustgarten Foundation and AACR

Additional Details

RFP Snapshot: The Lustgarten Foundation-AACR Career Development Award for Pancreatic Cancer Research, in Honor of Ruth Bader Ginsburg, has been established to honor the life and legacy of Justice Ginsburg, who worked tirelessly to advance gender equality, even while battling pancreatic cancer. The intent of this program is to support the development and diversity of talent working in pancreatic cancer research. Proposed projects may be in basic, translational, clinical, or population sciences related research and must have direct applicability and relevance to the understanding, detection, diagnosis, or treatment of pancreatic cancer and be aligned with the goals and priorities of the Lustgarten Foundation.

Max Amount and Period: $300,000 for 3 years

Eligibility: Eligibility is limited to female scientists engaged in pancreatic cancer research. Applicants must be at the rank of Instructor or Assistant Professor. Research Assistant Professor, Adjunct Assistant Professor, Assistant Professor Research Track, Visiting Professor are all eligible. Applicants must devote at least 75% of their total effort to pancreatic cancer research and have independent lab space. They must also be able to hold independent funding. Applicants must be AACR Active members. Nonmembers can apply for membership here.

Due Date: Letter of Intent Due: October 18, 2022 at Noon CST

October 18 LOI: AACR Career Development Award for Pancreatic Cancer Research in honor of John Robert Lewis – Lustgarten Foundation and AACR

Additional Details

RFP Snapshot: The Lustgarten Foundation-AACR Career Development Award for Pancreatic Cancer Research, in Honor of John Robert Lewis, has been established to honor the life and legacy of Representative Lewis, who worked tirelessly to advance the civil rights of all Americans, even while battling pancreatic cancer. The intent of this program is to support the development and diversity of talent working in pancreatic cancer research. Proposed projects may be in basic, translational, clinical, or population sciences related research and must have direct applicability and relevance to the understanding, detection, diagnosis, or treatment of pancreatic cancer and be aligned with the goals and priorities of the Lustgarten Foundation.

Max Amount and Period: $300,000 for 3 years

Eligibility: Eligibility is limited to members of racial or ethnic groups that have been shown to be underrepresented in the cancer related sciences workforce. Applicants must be at the rank of Instructor or Assistant Professor. Research Assistant Professor, Adjunct Assistant Professor, Assistant Professor Research Track, Visiting Professor are all eligible. Applicants must devote at least 75% of their total effort to pancreatic cancer research and have independent lab space. They must also be able to hold independent funding. Applicants must be AACR Active members. Nonmembers can apply for membership here.

Due Date: Letter of Intent Due: October 18, 2022 at Noon CST

October 18 LOI: Bladder Cancer Translational Clinical Trial Award – Bladder Cancer Advocacy Network

Additional Details

RFP Snapshot: BCAN is soliciting research proposals through this mechanism that address methods to reduce the burden of care and overtreatment for bladder cancer patients throughout the continuum of patient care including bladder cancer screening, diagnosis, and treatment of early and advanced stages.

Max Amount and Period: $3M over 3 years (clinical trials) OR $1M over 3 years (all other studies)

Eligibility: Applicants must be full-time, independent investigators with a degree of PhD, MD, DO, PharmD, ScD, or equivalent in the biomedical sciences. Study teams must be composed of at least two investigators and there must be at least one young investigator embedded as an integral contributor to the study team.

Due Date: Letter of Intent Due: October 18, 2022 at Noon CST

October 19: Young Investigator Award – Melanoma Research Alliance

Additional Details

RFP Snapshot: Young Investigator Awards aim to attract early career faculty with original ideas into the field of melanoma, thereby recruiting and supporting the next generation of melanoma research leaders. Awardees will be provided funding to accomplish innovative and original, preclinical, translational, and/or early clinical research projects.

Max Amount and Period: $255,000 over 3 years

Eligibility: Applicants must be within the first five years of their first independent, full time academic faculty appointment at the application deadline, at the level of Assistant Professor (or equivalent position). Mentorship from senior investigator is required. Applicants who are in research support positions are not eligible to apply.

Due Date: Eligibility Checklist Due: October 19, 2022 at 10:59PM CST

Special Opportunity #1: Bristol Myers Squibb-MRA YIA in Immunotherapy

Through the generous support of Bristol Myers Squibb (BMS), MRA is offering two awards for Young Investigators to conduct projects supported by preliminary data and focused on advancing immunotherapies in melanoma. Applicants should submit to the general Young Investigator Award program and designate their desire to be considered for this award when completing their online application in proposalCENTRAL. The same eligibility requirements above apply.

Special Opportunity #2: ASTRO-MRA YIA in Radiation Oncology

The MRA is pleased to partner with the American Society for Radiation Oncology (ASTRO) to offer a special opportunity to support research in radiation oncology to improve treatment options for melanoma patients. Early career radiation oncologists, radiation or cancer biologists, or physicists are encouraged to submit radiation oncology Research Proposals that include at least 50% effort on melanoma. The same eligibility requirements above apply. Applicants must be a member in good standing of ASTRO at time of award activation. Applicants should submit to the general Young Investigator Award program and designate their desire to be considered for this award when completing their online application in Proposal Central. Selecting “ASTRO Radiation Oncology” will not limit an applicant’s opportunity to also be selected under the general Young Investigator Award, but instead is meant to expand opportunities in an effort to increase overall funding of radiation oncology approaches for melanoma.

October 20: Conquer Cancer Career Development Award – Conquer Cancer, The ASCO Foundation

Additional Details

RFP Snapshot: The Career Development Award provides research funding to clinical investigators. This is a mentored award and the research project is conducted under the guidance of a scientific mentor. The research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects. Proposals with a predominant focus on in vitro or animal studies (even if clinically relevant) are not allowed.

Max Amount and Period: $200,000 over 3 years

Eligibility: Eligible applicants must be physicians (MD, DO, or equivalent) in the 1st to 3rd year of full-time faculty appointment with a scientific mentor. Applicants must be able to commit at least 50% of full-time effort in research (applies to total research, not just the proposed project) during the award period.

Applicants may not have other career development awards from private foundations during the CDA-supported project term. Applicants with concurrent federal career development awards and/or institutional training grants are eligible to apply, provided that are no scientific and budgetary overlaps. Past recipients of training fellowships are eligible to apply. Applicants must be ASCO members. Nonmembers must apply for membership here prior to grant submission.

Due Date: October 20, 2022 at 10:59PM CST

October 27 WUSTL INTERNAL SELECTION: Young Investigator Awards – Cancer Research Foundation

Additional Details

RFP Snapshot: These grants are designed to nurture young scientists in the pursuit of independent hypotheses, and to enable them to develop the preliminary data necessary to successfully compete for major research grants. The Cancer Research Foundation is particularly interested in funding research focused on decoding the mechanics of cancer, its development, diagnosis and treatment, using epigenetics, genomics, informatics, molecular and biochemical engineering, or image-oriented research. Projects connected to cancer from related “bench science” fields, such as chemistry, will be considered.

Max Amount and Period: $100,000 over 2 years

Eligibility: This competition is only for WUSTL Instructors or Assistant Professors within the first two years of their tenure-eligible faculty appointment. Preference will be given to recently appointed investigators who have been in their positions for less than one year, including those who will begin their positions in Fall 2022. Investigators with independent, peer-reviewed research funding are not eligible (exceptions have been made for NIH K awards).

Due Date: October 27, 2022 at 11:59PM CST

Additional Note: WUSTL will nominate up to THREE candidates.

November Deadlines

November 1 LOI: GFCR Grant Program – Gateway for Cancer Research

Additional Details

RFP Snapshot: These core grants fund early phase clinical trials for cancers of all types at renowned institutions around the world.

Max Amount and Period: $200,000 to $1.5M over 2-5 years

Eligibility: Any investigator who is ready to conduct a novel clinical trial in cancer research—one which will have an immediate impact on cancer patients—may apply for funding. The following research areas are prioritized by the Foundation: biomarkers/molecular markers (genomic or proteomic), gene therapy, histology agnostic/basket trial, immunotherapy, and targeted therapies.

Due Date: Letter of Intent Due: November 1, 2022 at 11:59PM CST

November 1 LOI: GFCR Integrative Program – Gateway for Cancer Research

Additional Details

RFP Snapshot: Gateway is focused on funding integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment.

Max Amount and Period: $200,000 to $1.5M over 2-5 years

Eligibility: Any investigator who is ready to conduct a novel clinical trial in cancer research—one which will have an immediate impact on cancer patients—may apply for funding. The following research areas are prioritized by the Foundation: biomarkers/molecular markers (genomic or proteomic), gene therapy, histology agnostic/basket trial, immunotherapy, and targeted therapies.

Due Date: Letter of Intent Due: November 1, 2022 at 11:59PM CST

November 1 LOI: SIO Integrative Program – Gateway for Cancer Research

Additional Details

RFP Snapshot: To bring the most promising patient-centered, integrative oncology research proposals forward, Gateway is partnering with SIO to support integrative clinical trials conducted by principal investigators and institutions among its membership.

Max Amount and Period: $200,000 to $1.5M over 2-5 years

Eligibility: Any investigator who is ready to conduct a novel clinical trial in cancer research—one which will have an immediate impact on cancer patients—may apply for funding. The following research areas are prioritized by the Foundation: biomarkers/molecular markers (genomic or proteomic), gene therapy, histology agnostic/basket trial, immunotherapy, and targeted therapies.

Due Date: Letter of Intent Due: November 1, 2022 at 11:59PM CST

November 1: Michael F. Price Memorial Grant Award for Gastroesophageal Cancer – DeGregorio Family Foundation

Additional Details

RFP Snapshot: The Foundation seeks to promote and facilitate collaborative research on the pathogenesis, early diagnosis and treatment of upper gastrointestinal malignancies. We support high quality, innovative and transformative translational and bench research to improve the understanding of the biology of these diseases, identification of potential novel therapeutic targets, or in the development and evaluation of novel biomarkers for early diagnosis and treatment.  Pre-clinical research, basic mechanistic studies, genomic/epigenomic studies as well as epidemiologic studies may also be supported.

Max Amount and Period: $250,000 over 2 years

Eligibility: Postdocs are not eligible for this award.

Due Date: November 1, 2022 at 10:59PM CST

November 1 LOI: NCI / SPORE Program – Gateway for Cancer Research

Additional Details

RFP Snapshot: The Gateway for Cancer Research is partnering with the NCI to give SPORE recipients the opportunity to apply for supplemental funding for their early phase, innovative clinical trials. The Gateway funding could enable principal investigators and their respective institutions to start a new trial by adding an additional arm, add patient cohorts and/or new correlative analysis.  Funding cannot duplicate scope of work of the SPORE award.

Max Amount and Period: $200,000 to $800,000 over 2-5 years

Eligibility: Applicants must be current SPORE recipients and be able to demonstrate that their project is in line with the Gateway’s mission.

Due Date: November 1, 2022 at 10:59PM CST

November 1: ASPIRE Grants: A Supplement to Promote Inclusion for Research Excellence – Susan G. Komen

Additional Details

RFP Snapshot: This new Susan G. Komen grant is intended to enhance the diversity of the breast cancer research workforce by providing established breast cancer scientists with supplemental funding to support research trainees from communities historically minoritized and marginalized in research. By supporting these promising trainees early in their research careers, Komen seeks to ensure that a diverse group of highly trained scientists who reflect the communities we serve will emerge as the next generation of leaders in breast cancer research and end breast cancer forever.

Max Amount and Period: $160,000 over 2 years

Eligibility: Applicant/PI will serve as the Lead Mentor for the Trainee supported by this grant supplement and must hold a tenure-track faculty position with adequate space for an additional trainee. The PI must have a currently funded breast cancer research project that has undergone rigorous peer review by Susan G. Komen, the Department of Defense, the NIH, or the NSF and the project must have at least one year of grant funds remaining at the time of award (on or around April 15, 2023). The applicant is not required to be a U.S. citizen or permanent resident. Trainees supported through this supplement are from the following racial and ethnic groups that have been shown to be underrepresented in biomedical research from NSF data. For more information on this grant and for full eligibility guidelines for the PI and the trainee, please see attached RFA.

Due Date: November 1, 2022 at Noon CST

November 2: Established Investigator Award – Melanoma Research Alliance

Additional Details

RFP Snapshot: Established Investigator Awards support senior investigators with an established record of scientific productivity and accomplishment.

Max Amount and Period: $375,000 over 3 years

Eligibility: Applicants must be senior investigators, past the five years of their first academic faculty appointment. Applicants must hold a full-time faculty appointment at the level of Assistant Professor (or equivalent) or above.

Due Date: November 2, 2022 at 10:59PM CST

November 2: Established Investigator Award in Industry Partnership – Melanoma Research Alliance

Additional Details

RFP Snapshot: The Academic-Industry Partnership Award (for Established Investigators) is designed to enhance translational research by extending academic capabilities to clinical investigations and to facilitate interactions between the academic and industrial research sectors. These awards will be co-funded by MRA and an industry partner whose involvement is essential to the project.

Max Amount and Period: $375,000 over 3 years

Eligibility: Applicants must be senior investigators, past the five years of their first academic faculty appointment. Applicants must hold a full-time faculty appointment at the level of Assistant Professor (or equivalent) or above. Applicant must identify an industry partner at the time of application.

Due Date: November 2, 2022 at 10:59PM CST

November 2: Pilot Award for Senior Investigators – Melanoma Research Alliance

Additional Details

RFP Snapshot: Pilot Awards support senior investigators who propose potentially transformative ideas that do not have extensive preliminary data but articulate a clear hypothesis and translational goals. Resources for such “high-risk, high-reward” projects are important to establish proof-of-concept, which may then leverage additional funding through more traditional avenues.

Max Amount and Period: $100,000 over 2 years

Eligibility: Applicants must be senior investigators, past the initial five years of their first academic faculty appointment, and must hold a full-time faculty appointment at the level of Assistant Professor (or equivalent) or above.

Due Date: November 2, 2022 at 10:59PM CST

Special Opportunity: ACIS-MRA Pilot Awards in Metastatic Uveal Melanoma

This opportunity is offered in partnership with A Cure In Sight (ACIS) to support research focused on metastatic uveal melanoma. Applicants should submit to the general Pilot Award program and designate their desire to be considered for this award when completing their online application in Proposal Central. Selecting “ACIS Metastatic Uveal” will not limit an applicant’s opportunity to also be selected under the general Pilot Award program, but instead is meant to expand opportunities in an effort to increase overall funding of metastatic uveal melanoma. The same eligibility requirements above apply.

November 7: Consortium on Translational Research in Early Detection of Liver Cancer: Translational Research Centers (U01 Clinical Trial Optional) – NIH/NCI

Additional Details

RFP Snapshot: This Funding Opportunity Announcement (FOA) is soliciting applications for a Liver Cancer Consortium focused on advancing translational research in the early detection of liver cancer. Translational Research Centers (TRCs) will conduct studies to improve the surveillance of liver cancer in members of high-risk populations, increase the fraction of liver cancer detected at an early stage, and better stratify patients at risk of developing liver cancer. A major collaborative effort of the TRCs will be establishing an integrated blood and image repository with annotated clinical data from patients found to have indeterminate nodules during liver cancer surveillance. To achieve these goals, each proposed TRC should include laboratory and clinical researchers with multi-disciplinary expertise in such areas as early cancer detection, biomarkers, cancer surveillance, imaging, and biospecimen science.

Max Amount and Period: $2.75M over 5 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.

For administrative, letter of intent, and FOA-related inquiries, please contact:

Matthew Young, Ph.D.
240-276-5846
youngma@mail.nih.gov

Due Date: November 7, 2022 at 5PM CST

November 7: Consortium on Translational Research in Early Detection of Liver Cancer: Data Management and Coordinating Center (U24 Clinical Trial Not Allowed) – NIH/NCI

Additional Details

RFP Snapshot: This Funding Opportunity Announcement (FOA) is a part of an initiative designed to establish a Liver Cancer Consortium to advance translational research focused on early detection of liver cancer. The DMCC will support the TRCs and coordinate trans-Consortium activities with the following specific responsibilities:

  • Overall administrative and logistical coordination for the Liver Cancer Consortium;
  • Support for Consortium collaborative research studies and biospecimen collections, including protocol development, data processing, statistical support, and computational analysis; and
  • Consortium data management, including developing and maintaining an integrated database of research data generated by the consortium, as well as management of all data relevant to biospecimens used in TRC studies (including clinical data annotations, and specimen usage tracking).

To achieve these goals, the DMCC is expected to provide multi-disciplinary expertise in liver cancer research, biomarkers for cancer detection, biostatistics, bioinformatics, and the information technology infrastructure to support data management for the Consortium.

Max Amount and Period: $2M over 5 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.

For administrative, letter of intent, and FOA-related inquiries, please contact:

Guillermo Marquez
240-276-7035
marquezg@mail.nih.gov

Due Date: November 7, 2022 at 5PM CST

November 14 LOI: Advanced Clinical Research Award for Diversity and Inclusion in Breast Cancer Research – Conquer Cancer / The ASCO Foundation

Additional Details

RFP Snapshot: This award is designed with the primary goal of increasing diversity in the oncology workforce and cancer research. Awards will be given to mid-career investigators who are members of racial and/or ethnic groups traditionally excluded in academic medicine and biomedical research, and who wish to conduct original breast cancer research not currently funded.

Max Amount and Period: $450,000 over 3 years

Eligibility: Applicants must self-identify as a member of a racial and/or ethnic group traditionally excluded in academic medicine according to the AAMC definition, which includes but is not limited to: American Indian/Alaska Native, Black/African American, Hispanic/Latinx, and Native Hawaiian/Other Pacific Islander. Applicants must also be physicians (MD, DO, or international equivalent) at mid-career level (between five and ten years from first full-time faculty appointment) and be able to commit 75% of full-time effort in research. Applicants must be able to demonstrate the ability to undertake independent, investigator-initiated clinical research in breast cancer. Nonmembers must apply for membership here prior to grant submission.

Due Date: Letter of Intent Due: November 14, 2022 at 10:59PM CST

November 15 LOI: Phase 2 Clinical Trial in Recurrent Osteosarcoma Patients – Osteosarcoma Institute

Additional Details

RFP Snapshot: The primary objective of clinical studies should be to improve event free survival (EFS) at 4 months, beyond historical rates known to be in the range of 12%. The proposed study may be carried out in a single institution, a clinical trial consortium, or through an existing clinical trial infrastructure. OSI will not prioritize the launch of new infrastructures to conduct clinical trials. The expectation is that results will be available within three years of study initiation.

Max Amount and Period: $800,000 over 2-3 years

Eligibility: No specified eligibility guidelines.

Due Date: Letter of Intent Due: November 15, 2022 at 4PM CST

November 15 LOI: Translational and Preclinical Research in Osteosarcoma – Osteosarcoma Institute

Additional Details

RFP Snapshot: Applicants are encouraged to describe how their proposal will contribute to the establishment of a preclinical dataset for osteosarcoma metastasis drug development. An ideal dataset would have the following features:

  • a drug target demonstrated to be relevant in osteosarcoma, rigorously and mechanistically tested in multiple preclinical models across preclinical model species, and in human osteosarcoma cells and/or lesions;
  • the availability of a therapeutic candidate or drug suitable for preclinical studies and future human translation – a testable PD marker of effective drug exposure;
  • a correlative biomarker that may be translated to human patients in support of optimal dosing.

Max Amount and Period: $500,000 over 2 years

Eligibility: No specified eligibility guidelines.

Due Date: Letter of Intent Due: November 15, 2022 at 4PM CST

November 15 LOI: Correlative Science Supporting Clinical Studies – Osteosarcoma Institute

Additional Details

RFP Snapshot: Correlative studies should seek to generate data in support of clinical studies seeking to improve event free survival (EFS) of recurrent and metastatic osteosarcoma patients. Our highest priority for correlative science proposals are those that will create the opportunity, should the associated clinical study fail, to understand the reasons for that failure, and allow for productive iteration of the approach.

Max Amount and Period: $250,000 to $500,000 over 2 years

Eligibility: No specified eligibility guidelines.

Due Date: Letter of Intent Due: November 15, 2022 at 4PM CST

November 15 LOI: Technology Impact Award – Cancer Research Institute

Additional Details

RFP Snapshot: These grants aim to encourage collaboration between technology developers and clinical cancer immunologists and to generate the proof-of-principle of a novel platform technology in bioinformatics, ex vivo or in silico modeling systems, immunological or tumor profiling instrumentation, methods, reagents and assays, or other relevant technologies that can enable clinician scientists to generate deeper insights into the mechanisms of action of effective or ineffective cancer immunotherapies.

Max Amount and Period: $200,000 over 2 years

Eligibility: Applicants must hold a faculty appointment as a tenure-track Assistant Professor (or higher rank) at the time of award activation. The grant will be awarded to a scientist who describes an extraordinarily novel, yet practical research plan that is creative and technically sophisticated. Selected projects that meet their 12 and 24 month milestones may be eligible for follow-on funding that will enable the established proof-of-concept technology to be developed into a methodology that improves cancer immunotherapy research worldwide.

Due Date: Letter of Intent Due: November 15, 2022 at 4PM CST

November 21: PanCAN Career Development Award – Pancreatic Cancer Action Network

Additional Details

RFP Snapshot: This award represents an effort to encourage and support early-career faculty to conduct pancreatic cancer research and establish successful career paths in the field. The research proposed for funding may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to pancreatic cancer. Special consideration will be given to understudied areas in pancreatic cancer research, minority researchers, and research focused on cancer health disparities.

Max Amount and Period: $250,000 over 2 years

Eligibility: Applications must hold a title of Instructor, Assistant Professor, or Research Assistant Professor or equivalent and must have completed their most recent doctoral degree within the past 11 years. They must have independent lab space and not have currently or previously served as a PI on major research awards or grants (NIH R00, NIH R01, or equivalent).

Due Date: November 21, 2022 at 11PM CST